Association between HLA-DRB1*04:05 and the efficacy of immune checkpoint inhibitors for patients with advanced cancer - Top-Institutions - MDSpire

Association between HLA-DRB1*04:05 and the efficacy of immune checkpoint inhibitors for patients with advanced cancer

  • By

  • Mayu Watanabe

  • Jun Eguchi

  • Atsushi Takamoto

  • Jun Wada

  • June 10, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Okayama University
    Okayama University

    Okayama, Okayama

    Key Differentiators

    • Oncology

  • #2

    Center for Cancer Immune Therapy, Herlev Hospital
    Center for Cancer Immune Therapy, Herlev Hospital

    Herlev, Copenhagen

    Key Differentiators

    • Oncology

  • #3

    Herlev and Gentofte Hospital
    Herlev and Gentofte Hospital

    Herlev, Copenhagen

    Key Differentiators

    • Oncology

  • #4

    Garvan Institute of Medical Research
    Garvan Institute of Medical Research

    Sydney, New South Wales

    Key Differentiators

    • Oncology

Original Source(s)

Association between HLA-DRB1*04:05 and the efficacy of immune checkpoint inhibitors for patients with advanced cancer

  • by Mayu Watanabe, Jun Eguchi, Atsushi Takamoto, Jun Wada

  • June 10, 2026

Related Content

The value of robot-assisted gastrectomy in the treatment of gastric cancer: a systematic review and meta-analysis

Cross-platform evaluation of LLM-generated educational texts on cardiac myxoma: quality, readability, and actionability using network analysis and latent profile analysis

Hetairos is a histology-based artificial intelligence model for predicting central nervous system tumor methylation subtypes